Over 1 in 4 drugs approved in US delayed by FDA complete response letters
This article was originally published in SRA
Executive Summary
More than one in four drugs approved by the US Food and Drug Administration between fiscal years 2009 and 2012 were hit with complete response letters (CRLs) from the agency during the review process and had to be resubmitted before they were finally approved1.